GlassScriptPhysician profile
George L Hamrick
NPI 1497754659
$9,597.76
in general payments reported to CMS, 2019-2025
31 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $291 · 2021: $1,761 · 2022: $378 · 2023: $813 · 2024: $5,047 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,759 · Travel and Lodging: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.16 |
| Travel and Lodging | $2,593.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,381.99 | 2019-2025 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $1,097.45 | 2021-2025 | Plasmablade(Tm), Cobalt Dr Mri Surescan, Selectsecure |
| Abbott Laboratories | $1,036.76 | 2019-2025 | Tendril, Aveir, Perclose Prostyle |
| Biotronik INC. | $592.39 | 2019-2024 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Impulse Dynamics (USA) INC. | $459.61 | 2023-2025 | Optimizer, Optimizer |
| Pfizer INC. | $331.72 | 2019-2025 | |
| Irhythm Technologies, INC. | $294.86 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $287.94 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $244.42 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $189.16 | 2019-2025 | Camzyos |
| Edwards Lifesciences Corporation | $98.56 | 2025 | Evoque |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.02 | 2019-2024 | Lifevest |
| Celgene Corporation | $70.64 | 2023-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $54.71 | 2019-2025 | Farxiga |
| Ethicon US, LLC | $40.27 | 2025 | Ethicon, Stratafix, Monocryl |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.80 | 2019-2020 | |
| Esperion Therapeutics, INC. | $33.80 | 2021-2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $25.85 | 2019 | |
| Heartflow, INC. | $24.91 | 2025 | |
| Elutia, INC. | $22.60 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $22.54 | 2023 | Arcalyst |
| Smith+Nephew, INC. | $21.85 | 2024 | Pico, Renasys Touch |
| Genzyme Corporation | $20.18 | 2023 | |
| Davol INC. | $19.61 | 2021 | |
| Kestra Medical Technology Services, INC. | $18.32 | 2023 | Assure Wcd |
| Medtronic Vascular, INC. | $17.50 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.41 | 2025 | |
| Merck Sharp & Dohme LLC | $15.22 | 2025 | Verquvo |
| Bardy Diagnostics, INC. | $14.00 | 2019 | |
| Nuwellis, INC. | $12.36 | 2019 | |
| Altathera Pharmaceuticals LLC | $11.31 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Hamrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.